---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000019"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:54:21.220946+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q4 net loss $85.8M, cash $448.7M; ALPHA3 trial to start mid-2024

## Summary
- Net loss Q4 2023 $85.8M ($0.51/share); full-year net loss $327.3M ($2.09/share).
- Cash, cash equivalents & investments $448.7M as of Dec 31, 2023; cash runway into 2026 reaffirmed.
- 2024 GAAP op. expenses ~$280M; expected cash burn ~$190M; non-cash comp ~$60M.
- Pivotal cema-cel ALPHA3 1L LBCL trial enrollment begins mid-2024; randomized 230 MRD+ patients.
- ALLO-329 (CD19 Dagger) for autoimmune disease to enter Phase 1 in early 2025; Arbor Biotechnologies licensing deal.

## SEC filing metadata
- accession: 0001737287-24-000019
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000019/0001737287-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000019/allo-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000019
- JSON: https://secwatch.observer/filing/0001737287-24-000019.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000019.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2023.
  - Period: fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 14, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000019/0001737287-24-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.